GHCL Announces Buyback This Week: Tender Offer ₹300 Cr at ₹725 — Record Date Nov 14, 2025
10 Nov 2025
India Gelatine & Chemicals Limited - Manufacturing Facility and Production Unit
📊 Stock Analysis
Complete financial analysis with key metrics and investment outlook
India Gelatine & Chemicals Q2 FY2026 Financial Performance
India Gelatine & Chemicals Limited (BSE: 531253) reported a robust set of results for the quarter ended September 30, 2025 (Q2 FY26), delivering strong revenue and profit growth with a remarkable improvement in operating margins.
The company’s focus on higher-value gelatin and chemical products, cost optimization, and operational efficiency resulted in record profitability this quarter.
Stock Performance & Key Metrics
As of November 10, 2025 (close price):
- Current Price: ₹355
- Today’s Change: +10.74%
- Market Cap: ₹252 Crores
- High / Low (₹): 450 / 306
- Stock P/E: 11.1
- Industry P/E: 30.7
- Book Value: ₹256
- Dividend Yield: 1.41%
- ROCE: 11.9%
- ROE: 9.22%
- Face Value: ₹10
- EPS (TTM): ₹32.1
- Debt to Equity: 0.03
- Debt: ₹5.27 Crores
- PEG Ratio: 0.24
Q2 FY2026 Consolidated Financial Highlights
| Particulars | Q2 FY26 (Sep 2025) | Q1 FY26 (Jun 2025) | Q2 FY25 (Sep 2024) | YoY Change |
|---|---|---|---|---|
| Revenue / Sales | ₹46.9 Cr | ₹39.1 Cr | ₹42.7 Cr | ↑ 10% |
| EBITDA | ₹8.63 Cr | ₹7.90 Cr | ₹3.70 Cr | ↑ 133% |
| Net Profit (PAT) | ₹6.44 Cr | ₹7.08 Cr | ₹3.09 Cr | ↑ 108% |
| EPS (₹) | 9.08 | 9.98 | 4.36 | ↑ 108% |
Performance Overview
The company reported 10% YoY growth in sales on strong product demand from pharmaceutical and food-grade gelatin markets. EBITDA and PAT margins expanded sharply due to operational leverage and stable input costs, resulting in a 108% rise in net profit year-over-year.
Management Commentary
The management credited improved product mix and plant utilization efficiency for the record performance. The company remains focused on maintaining profitability through process optimization and cost discipline.
> “Q2 FY26 was a strong quarter marked by margin expansion and better realizations. We continue to emphasize quality manufacturing and value-added gelatin applications,” management said.
Strategic Highlights
- Robust demand from pharma, nutraceutical, and food industries.
- Improved cost structure through better raw material sourcing and efficiency gains.
- Balance sheet remains strong and debt-light, with minimal borrowings of ₹5.27 Cr.
- Focus on exports and specialty gelatin segments for long-term growth.
Business Overview
Founded in 1973, India Gelatine & Chemicals Ltd manufactures gelatin, ossein, and related collagen-based products used in pharmaceuticals, food, and photography. The company has a longstanding reputation in the chemicals and allied industries.
Financial Strength
The company’s low leverage (Debt-to-Equity 0.03) and strong operational metrics underscore financial stability. With ROE at 9.2% and ROCE at 11.9%, India Gelatine continues to efficiently utilize its capital base.
Outlook
Management expects continued revenue growth led by:
- Expanding demand in pharma-grade gelatin and nutraceuticals.
- Operational efficiencies driving sustainable margins.
- Ongoing cost control and improved capacity utilization.
India Gelatine remains a solid small-cap play on the specialty chemicals and ingredients theme with consistent profitability and a healthy balance sheet.
*For full results, refer to the official filing:* https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=07da114f-59d3-48a0-b360-87e164e4f2ec.pdf
*Data as of November 10, 2025 | Results approved by Board of Directors on November 10, 2025*
